
Fulltext:
177025.pdf
Embargo:
until further notice
Size:
262.8Kb
Format:
PDF
Description:
publisher's version
Publication year
2017Source
Antimicrobial Agents and Chemotherapy, 61, 9, (2017), pp. e00915-17, article e00915-17ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Clinical Pharmacy
Paediatrics
Paediatrics - OUD tm 2017
Medical Microbiology
Intensive Care
Pharmacology-Toxicology
Internal Medicine
Journal title
Antimicrobial Agents and Chemotherapy
Volume
vol. 61
Issue
iss. 9
Page start
p. e00915-17
Page end
p. e00915-17
Subject
Radboudumc 11: Renal disorders RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences; Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life SciencesAbstract
Combining voriconazole and flucloxacillin is indicated in patient cohorts experiencing both invasive aspergillosis and Gram-positive infections (e.g., patients with chronic granulomatous disease or postinfluenza pulmonary aspergillosis). We report a highly relevant interaction between voriconazole and flucloxacillin, resulting in subtherapeutic plasma voriconazole concentrations in more than 50% of patients, that poses a severe threat if not managed properly.
This item appears in the following Collection(s)
- Academic publications [227693]
- Electronic publications [107311]
- Faculty of Medical Sciences [86198]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.